Aytu Bioscience acquires rights to Natesto drug

Aytu Bioscience acquires rights to Natesto drug

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced the exclusive licensing... Read More

Monday April 25, 2016 0 comments Tags: Aytu BioScience, Englewood, Natesto, Acerus Pharma, Josh Disbrow, Tom Rossi

Aytu BioScience awarded Health Canada approval for its MiOXSYS™ system for male infertility

Aytu BioScience awarded Health Canada approval for its MiOXSYS™ system for male infertility

ENGLEWOOD -- Aytu BioScience, Inc . (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on global commercialization of novel products in the field of urology, announced it has... Read More

Wednesday April 6, 2016 0 comments Tags: Englewood, Josh Disbrow, Aytu BioScience, MiOXSYS

Aytu BioScience announces U.S. co-promotion agreement for Primsol

Aytu BioScience announces U.S. co-promotion agreement for Primsol

ENGLEWOOD -- Aytu BioScience , Inc.(OTCQX: AYTU), a commercial-stage specialty healthcare company focused on commercializing treatments for urological conditions, today announced the company... Read More

Tuesday March 29, 2016 0 comments Tags: Englewood, Aytu BioScience, Primsol, Josh Disbrow, Allegis Pharmaceuticals

Aytu Bioscience announces first sales for male infertility system

Aytu Bioscience announces first sales for male infertility system

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a commercial-stage specialty healthcare company focused on commercializing treatments for urological conditions, today announced the first... Read More

Tuesday February 9, 2016 0 comments Tags: Aytu BioScience, Josh Disbrow, Englewood, MiOXSYS, male infertility

Aytu adds two founders to board of directors

Aytu adds two founders to board of directors

ENGLEWOOD -- Aytu BioScience, Inc .(OTCQX: AYTU), a specialty healthcare company focused on commercializing treatments for urological and related conditions, announced Josh Disbrow , Aytu''s... Read More

Thursday January 28, 2016 0 comments Tags: Aytu BioScience, Josh Disbrow, Jarrett Disbrow, Englewood, Michael Macaluso, MiOXSYS

Aytu appoints Jonathan Heath McGrael VP of sales

Aytu appoints Jonathan Heath McGrael VP of sales

ENGLEWOOD-- Aytu BioScience Inc . (OTCQB: AYTU), a specialty health care company developing treatments for urological and related conditions, announced the appointment of Jonathan Heath McGrael ... Read More

Thursday September 10, 2015 0 comments Tags: Englewood, Aytu BioScience, Jonathan Heath McGra, Josh Disbrow, ProstaScint

Aytu BioScience closes on $5.175M note financing

Aytu BioScience closes on $5.175M note financing

ENGLEWOOD-- Aytu BioScience Inc . (OTCQB: AYTU), a specialty health care company focused on developing treatments for urological and related conditions, announced it has closed on the final... Read More

Thursday September 3, 2015 0 comments Tags: Englewood, Aytu BioScience, Josh Disbrow, Zertane, RedoxSYS, ProstaScint

Aytu to acquire rights to Jazz Pharmaceuticals’ ProstaScint prostate detection drug

Aytu to acquire rights to Jazz Pharmaceuticals’ ProstaScint prostate detection drug

ENGLEWOOD-- Aytu BioScience Inc. (OTCMKTS: RSWN), a specialty health care company focused on developing treatments for urological and related conditions, today announced it entered into an... Read More

By: InnovatioNews Tuesday June 9, 2015 0 comments Tags: Englewood, Aytu BioScience, Jazz Pharmaceuticals, Josh Disbrow, ProstaScint, Zertane, RedoxSYS